Stock PHXM PHAXIAM THERAPEUTICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

End-of-day quote Euronext Paris
Other stock markets
 18:00:00 2024-05-16 EDT 		5-day change 1st Jan Change
3.055 EUR +0.16% Intraday chart for PHAXIAM Therapeutics S.A. +2.86% -33.59%
04-15 Phaxiam initiates trial in infective endocarditis CF
04-15 PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PHAXIAM provides Business and Financial Update for the First Quarter of 2024
GL
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
GL
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
GL
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
GL
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
GL
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
GL
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHXM Stock
  4. News PHAXIAM Therapeutics S.A.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW